Methods and Applications of Statistics in Clinical Trials
Volume 1: Concepts, Principles, Trials, and Designs
Methods and Applications of Statistics

1. Edition March 2014
992 Pages, Hardcover
Wiley & Sons Ltd
Short Description
This comprehensive book features both new and established material on the key statistical principles and concepts for designing modern-day clinical trials, such as hazard ratio, flexible designs, confounding, covariates, missing data, and longitudinal data. It discusses the various kinds of trials that can be found in today's clinical setting including open-labeled trials, multicentered trials, and superiority trials. It also explores such ongoing, cutting-edge trials as early cancer & heart disease, mother to child human immunodeficiency virus transmission, women's health initiative dietary, and AIDS.
A complete guide to the key statistical concepts essential for the design and construction of clinical trials
As the newest major resource in the field of medical research, Methods and Applications of Statistics in Clinical Trials, Volume 1: Concepts, Principles, Trials, and Designs presents a timely and authoritative reviewof the central statistical concepts used to build clinical trials that obtain the best results. The referenceunveils modern approaches vital to understanding, creating, and evaluating data obtained throughoutthe various stages of clinical trial design and analysis.
Accessible and comprehensive, the first volume in a two-part set includes newly-written articles as well as established literature from the Wiley Encyclopedia of Clinical Trials. Illustrating a variety of statistical concepts and principles such as longitudinal data, missing data, covariates, biased-coin randomization, repeated measurements, and simple randomization, the book also provides in-depth coverage of the various trial designs found within phase I-IV trials. Methods and Applications of Statistics in Clinical Trials, Volume 1: Concepts, Principles, Trials, and Designs also features:
* Detailed chapters on the type of trial designs, such as adaptive, crossover, group-randomized, multicenter, non-inferiority, non-randomized, open-labeled, preference, prevention, and superiority trials
* Over 100 contributions from leading academics, researchers, and practitioners
* An exploration of ongoing, cutting-edge clinical trials on early cancer and heart disease, mother-to-child human immunodeficiency virus transmission trials, and the AIDS Clinical Trials Group
Methods and Applications of Statistics in Clinical Trials, Volume 1: Concepts, Principles, Trials, and Designs is an excellent reference for researchers, practitioners, and students in the fields of clinicaltrials, pharmaceutics, biostatistics, medical research design, biology, biomedicine, epidemiology,and public health.
Preface xxix
1 Absolute Risk Reduction 1
References 11
Further Reading 12
2 Accelerated Approval 14
References 25
Further Reading 26
3 AIDS Clinical Trials Group (ACTG) 27
References 37
4 Algorithm-Based Designs 40
References 51
5 Alpha-Spending Function 53
References 61
Further Reading 63
6 Application of New Designs in Phase I Trials 65
References 72
Further Reading 73
7 ASCOT Trial 74
References 78
8 Benefit/Risk Assessment in Prevention Trials 80
References 87
9 Biased Coin Randomization 90
References 104
10 Biological Assay, Overview 106
References 122
Further Reading 124
11 Block Randomization 125
References 136
Further Reading 138
12 Censored Data 139
References 141
13 Clinical Data Coordination 146
References 162
14 Clinical Data Management 164
References 169
15 Clinical Significance 170
References 185
16 Clinical Trial Misconduct 191
References 202
17 Clinical Trials, Early Cancer and Heart Disease 205
References 213
18 Cluster Randomization 216
References 228
19 Coherence in Phase I Clinical Trials 230
References 238
20 Compliance and Survival Analysis 240
References 244
21 Composite Endpoints in Clinical Trials 246
References 251
22 Confounding 252
References 261
23 Control Groups 263
References 271
24 Coronary Drug Project 273
References 282
Further Reading 284
25 Covariates 285
References 296
26 Crossover Design 300
References 308
27 Crossover Trials 310
References 317
28 Diagnostic Studies 320
References 338
Further Reading 339
29 DNA Bank 340
References 350
30 Up-and-Down and Escalation Designs 353
References 359
Further Reading 361
31 Dose Ranging Crossover Designs 362
References 379
Further Reading 382
32 Flexible Designs 383
References 396
33 Gene Therapy 399
References 411
Further Reading 422
34 Global Assessment Variables 423
References 435
35 Good Clinical Practice (GCP) 438
References 446
Further Reading 446
36 Group-Randomized Trials 448
References 462
37 Group Sequential Designs 467
References 479
38 Hazard Ratio 483
Further Reading 499
References 499
39 Large Simple Trials 500
References 506
Further Reading 508
40 Longitudinal Data 510
References 514
Further Reading 514
41 Maximum Duration and Information Trials 515
References 521
42 Missing Data 522
References 533
43 Mother to Child Human Immunodeficiency Virus Transmission Trials 536
References 545
Further Reading 549
44 Multiple Testing in Clinical Trials 550
References 556
Further Reading 557
45 Multicenter Trials 558
Readings 569
References 569
46 Multiple Endpoints 570
References 575
47 Multiple Risk Factor Intervention Trial 577
References 583
Further Reading 586
48 N-of-1 Randomized Trials 587
References 596
49 Noninferiority Trial 598
References 605
50 Nonrandomized Trials 609
References 617
51 Open-Labeled Trials 619
References 623
Further Reading 624
52 Optimizing Schedule of Administration in Phase I Clinical Trials 625
References 632
53 Partially Balanced Designs 635
References 655
54 Phase I/II Clinical Trials 658
References 665
55 Phase II/III Trials 667
References 679
Further Reading 680
56 Phase I Trials 682
References 688
57 Phase II Trials 692
References 697
Further Reading 699
58 Phase III Trials 700
References 709
59 Phase IV Trials 711
References 717
Further Reading 718
60 Phase I Trials in Oncology 719
References 723
Further Reading 724
61 Placebos 725
References 732
62 Planning a Group-Randomized Trial 736
References 743
63 Postmenopausal Estrogen/Progestin Interventions Trial (PEPI) 744
References 754
Further Reading 756
64 Preference Trials 759
References 768
Further Reading 769
65 Prevention Trials 770
References 776
66 Primary Efficacy Endpoint 779
References 786
Further Reading 788
67 Prognostic Variables in Clinical Trials 789
References 797
68 Randomization Procedures 799
References 810
69 Randomization Schedule 813
References 825
Further Reading 826
70 Repeated Measurements 827
References 838
71 Simple Randomization 841
References 849
Further Reading 849
72 Subgroups 850
References 865
73 Superiority Trials 867
References 877
Further Reading 877
74 Surrogate Endpoints 878
References 885
75 TNT Trial 887
References 892
Further Reading 893
76 UGDP Trial 894
References 914
77 Women's Health Initiative Hormone Therapy Trials 918
References 928
78 Women's Health Initiative Dietary Modification Trial 931
References 943
Index 945